RESUMO
AIMS: To evaluate in patients with heart failure (HF) due to systolic dysfunction the occurrence of polypharmacy, alternative medicine, immunization against influenza, and patients' knowledge about their medication. METHODS AND RESULTS: Sixty-five patients, 49 men, mean age 60.5+/-12.0 years answered a confidential questionnaire during 2002. Polypharmacy was frequent, 48 (74%) were taking six or more pills per day and 18 (28%) 11 or more. Fifteen patients (23%) used over-the-counter analgesics. Eight patients (12%) used alternative medicine [five women (31%) vs. three men (6%), P=0.02]. Forty-four patients (68%) received immunization against influenza (18 patients <65 years (54%) vs. 25 patients > or =65 years (79%), P=0.03). Half the patients knew that beta-blockers and vasodilators decreased blood pressure, 31 patients receiving diuretics (88%) knew that this drugs help to eliminate liquids, 12 patients (38%) recognized this effect with low dose spironolactone and 23% or less with other drugs. Only 12 patients (42%) treated with acenocoumarol and 13 of those treated with aspirin (32%) recognized the action of these drugs. CONCLUSION: Patients with HF and systolic dysfunction have a poor knowledge about the medication they receive. Polypharmacy, over-the-counter, homeopathic and alternative medicine use is frequent whereas the rate of immunization against influenza is low.
Assuntos
Terapias Complementares , Conhecimentos, Atitudes e Prática em Saúde , Insuficiência Cardíaca/tratamento farmacológico , Imunização , Polimedicação , Adulto , Idoso , Fármacos Cardiovasculares/uso terapêutico , Terapias Complementares/métodos , Feminino , Humanos , Imunização/métodos , Influenza Humana/prevenção & controle , Masculino , Pessoa de Meia-Idade , Seleção de Pacientes , Inquéritos e QuestionáriosRESUMO
During the last 40 years vaccines have been developed that have greatly reduced the incidence of infectious diseases of dogs. In general, modified live products have been superior to inactivated vaccines for dogs. It can be expected that recombinant and/or DNA vaccines may dominate the market in the future. Although most vaccines on the market are safe and efficacious, there have been exceptions where disease was induced by vaccination or dogs were not protected. The failure of protection may in part be due to variations in individual vaccine batches. Only potency tests but not efficacy tests are required, which may not be sufficient. For example, a virus titer in a vaccine may be meaningless if the minimum protective dose is not known. Overattenuated virus (e.g., CDV-Ond or parvovirus in cat cells) may have a high titer in tissue culture but is not immunogenic. The question of frequency of vaccination of dogs should be addressed. Annual revaccinations for CDV, CPV, and CAV are probably not needed. However, it would be desirable to collect more data to support less frequent vaccinations. Annual immunization for bacterial diseases such as kennel cough, Lyme disease, and leptospirosis should continue. It also would be desirable to develop more oro/nasal vaccines, perhaps combined with newly developed vectors that are less likely to induce undesirable side effects that may be seen after parenteral vaccination. Finally a word of warning against homeopathic "nosodes" to replace tested canine vaccines. They will appear highly effective as long as the majority of dogs remain vaccinated. As soon as a nonvaccinated dog population is large enough to allow virulent agents to spread, disease outbreaks will occur and we will be back where we began 40 years ago.
Assuntos
Infecções Bacterianas/veterinária , Vacinas Bacterianas , Doenças do Cão/imunologia , Imunização/veterinária , Vacinação/veterinária , Vacinas Virais , Viroses/veterinária , Animais , Infecções Bacterianas/imunologia , Infecções Bacterianas/prevenção & controle , Gatos , Doenças do Cão/prevenção & controle , Cães , Imunização/métodos , Esquemas de Imunização , Vacinas de DNA , Viroses/imunologia , Viroses/prevenção & controleRESUMO
Se investigó la inmunogenicidad (seroconversión, seroprotección hiperrespuesta y media geométrica) producida por la vacuna recombinante cubana contra la hepatitis viral tipo B en nuestro medio, en un estudio multicentrico nacional, concurrente, aplicando el sistema de 0, 1, 2 meses en 211 trabajadores de la salud, susceptibles, pertenecientes al IPSS. La cuantificación del antiHBs se realizó por el método inmunoenzimático de Organon Tecknics. Se obtuvo un 97 por ciento de seroprotección en solo 75 días de haber iniciado el esquema, observandose una mayor inmunogenicidad en mujeres menores de 40 años. Se recomienda la aplicación de este esquema como parte del programa de control en la Hepatitis viral tipo B por su simetría, corta latencia y grado de protección